TY - JOUR
T1 - Attainment of low-density lipoprotein cholesterol goals in statin treated patients
T2 - Real-world evidence from Australia
AU - Talic, Stella
AU - Marquina, Clara
AU - Zomer, Ella
AU - Ofori-Asenso, Richard
AU - Petrova, Mariana
AU - Vargas Torres, Sandra
AU - Abushanab, Dina
AU - Wolfe, Rory
AU - Lybrand, Sean
AU - Thomson, David
AU - Stratton, Giles
AU - Liew, Danny
AU - Ademi, Zanfina
N1 - Funding Information:
The research team acknowledges funding and support from the AMGEN Australia Pty Ltd and to IQVIA for providing data for this study.
Funding Information:
ST, CM, MP, DA and ZA have nothing to declare; ROS is employed by Roche Holding AG. SL and DT are employed by Amgen Australia Ltd; GS is employed by IQVIA; EZ declares grants from Amgen, AstraZeneca, Pfizer and Shire, outside the submitted work; DL declares grants from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Pfizer and Sanofi, and past participation in advisory boards and/or receipt of honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Bristol- Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi and Shire, outside the submitted work.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/7
Y1 - 2022/7
N2 - Little is known about the attainment of low-density lipoprotein cholesterol (LDL-C) targets in patients treated with statins in Australian primary healthcare setting that are at increased risk of cardiovascular disease. A retrospective cohort study was conducted using data from electronic medical records of patients treated by general practitioners across Australia. LDL-C target attainment was defined as LDL-C levels ≤ 2 mmol/L for all risk groups, in line with Australian guidelines. Multivariable logistic regression was used to identify the factors associated with LDL-C target attainment. Overall, 61,407 patients were included in the analysis. The mean age was 65 years (± standard deviation [SD] 12.1); 52.0% were males. Overall, the median LDL-C level was 2.3 mmol/L (IQR = 1.8 - 2.8) and 36.0% of the study population met therapeutic targets. Increased likelihood to achieve LDL-C targets was observed in patients diagnosed with type 2 diabetes (OR 2.07, 95% CI 1.92 – 2.24), stroke (OR = 1.58, 95% CI 1.39 – 1.79, P < 0.001) or chronic heart disease (OR = 1.67, 95% CI 1.55 – 1.81, P < 0.001). Patients diagnosed with dyslipidemia (OR = 0.59, 95% CI 0.55 – 0.64, P < 0.001), hypertension (OR = 0.91, 95% CI 0.83 – 1.00, P < 0.05) and current smokers (OR = 0.71, 95% CI 0.71 – 1.00, P < 0.05), were less likely to attain LDL-C targets, regardless of the type, intensity and length of use of the prescribed statin. Longer duration and higher intensity statin were associated with more patients achieving targeted LDL-C goal, however nearly two thirds of Australians still failed to achieve targeted outcome even after 24 months of statin therapy.
AB - Little is known about the attainment of low-density lipoprotein cholesterol (LDL-C) targets in patients treated with statins in Australian primary healthcare setting that are at increased risk of cardiovascular disease. A retrospective cohort study was conducted using data from electronic medical records of patients treated by general practitioners across Australia. LDL-C target attainment was defined as LDL-C levels ≤ 2 mmol/L for all risk groups, in line with Australian guidelines. Multivariable logistic regression was used to identify the factors associated with LDL-C target attainment. Overall, 61,407 patients were included in the analysis. The mean age was 65 years (± standard deviation [SD] 12.1); 52.0% were males. Overall, the median LDL-C level was 2.3 mmol/L (IQR = 1.8 - 2.8) and 36.0% of the study population met therapeutic targets. Increased likelihood to achieve LDL-C targets was observed in patients diagnosed with type 2 diabetes (OR 2.07, 95% CI 1.92 – 2.24), stroke (OR = 1.58, 95% CI 1.39 – 1.79, P < 0.001) or chronic heart disease (OR = 1.67, 95% CI 1.55 – 1.81, P < 0.001). Patients diagnosed with dyslipidemia (OR = 0.59, 95% CI 0.55 – 0.64, P < 0.001), hypertension (OR = 0.91, 95% CI 0.83 – 1.00, P < 0.05) and current smokers (OR = 0.71, 95% CI 0.71 – 1.00, P < 0.05), were less likely to attain LDL-C targets, regardless of the type, intensity and length of use of the prescribed statin. Longer duration and higher intensity statin were associated with more patients achieving targeted LDL-C goal, however nearly two thirds of Australians still failed to achieve targeted outcome even after 24 months of statin therapy.
UR - http://www.scopus.com/inward/record.url?scp=85123889836&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2021.101068
DO - 10.1016/j.cpcardiol.2021.101068
M3 - Review Article
C2 - 34818528
AN - SCOPUS:85123889836
SN - 0146-2806
VL - 47
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 7
M1 - 101068
ER -
